Abstract on IMUNON's IMNN-001 and Bevacizumab Phase 2 Study Accepted for ASCO Annual Meeting

IMUNON, Inc. (NASDAQ: IMNN), a company based in Lawrenceville, New Jersey, and focused on non-viral DNA-mediated immunotherapy and advanced vaccines, has announced that a Phase 2 study involving their product IMNN-001 has been accepted for presentation at the upcoming American Society of Clinical Oncology (ASCO) annual meeting. The meeting is scheduled to take place in Chicago from May 31st to June 4th.

The study, titled “A phase II study evaluating the effect of IMNN-001 on second-look laparoscopy when administered in combination with bevacizumab and neoadjuvant chemotherapy in patients newly diagnosed with advanced epithelial ovarian cancer,” will be presented on June 3rd. The presentation will occur during the Gynecologic Cancer session between 9:00 a.m. and 12:00 p.m. CT, and will be led by Dr. Amir A Jazaeri, Professor of Gynecological Oncology & Reproductive Medicine at The University of Texas MD Anderson Cancer Center. The study is actively recruiting participants within the United States.

The specifics of the presentation are as follows:
- Abstract Number: TPS5633
- Poster Board Number: 498a
- Session Title: Gynecologic Cancer
- Location: Hall A

Dr. Sebastien Hazard, IMUNON's Chief Medical Officer, emphasized the importance of this study. He highlighted that the study is significantly funded by Break Through Cancer, with MD Anderson as the lead clinical site. He noted the promising synergy observed between IMNN-001 and bevacizumab in pre-clinical experiments. The goal is to quickly complete patient enrollment to address this important clinical question.

IMUNON is a clinical-stage biotechnology enterprise dedicated to developing a range of innovative treatments that leverage the body's natural mechanisms to produce safe, effective, and durable responses across various human diseases. This approach is intended to offer a distinct alternative to conventional therapies. The company is advancing its non-viral DNA technology through two primary modalities.

The first modality, TheraPlas®, is designed for coding proteins and cytokines to treat solid tumors using an immunological approach. The second modality, PlaCCine®, focuses on coding viral antigens that can trigger a strong immunological response. This technology could serve as a promising platform for developing vaccines against infectious diseases.

IMUNON's leading clinical program, IMNN-001, is a DNA-based immunotherapy currently in Phase 2 development for localized treatment of advanced ovarian cancer. IMNN-001 functions by instructing the body to produce high levels of cancer-fighting molecules such as interleukin-12 and interferon gamma directly at the tumor site. Additionally, the company is exploring the potential of its COVID-19 booster vaccine, IMNN-101, and is entering a first-in-human study for this application. IMUNON aims to continue leveraging these technological advancements to better serve patients with challenging medical conditions.

In conclusion, IMUNON's innovative approaches in DNA technology and immunotherapy are paving the way for new treatments against difficult-to-treat diseases, with promising developments in cancer therapy and vaccine platforms.